Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voronin + amoxicillin with or without Bacillus subtilis for Helicobacter pylori eradication and microbiome changes
ChiCTR2200064869Phase 4Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Oct 2022
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Helicobacter pylori infection, chronic gastritis, atrophic gastritis (AG) and 1 more comparing Voronin + amoxicillin + Bacillus subtilis with Voronin + amoxicillin + placebo (2 arms). Primary endpoints: H. pylori infection eradication rate, Intestinal microbiome sample and 1 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
amoxicillinbacillus subtilis
03
Conditions
Helicobacter pylori infectionchronic gastritisatrophic gastritis (AG)gastritis
Beyond the preview
Go deeper on ChiCTR2200064869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064869.